{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:39:06Z","timestamp":1774949946546,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","award":["2020-215611 (5384"],"award-info":[{"award-number":["2020-215611 (5384"]}],"id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91020F00003"],"award-info":[{"award-number":["75N91020F00003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ebiom.2021.103626","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T04:06:00Z","timestamp":1634875560000},"page":"103626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-9275","authenticated-orcid":false,"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Alshammary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8217","authenticated-orcid":false,"given":"Ariel","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Amanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Amoako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-4497","authenticated-orcid":false,"given":"Ana Silvia","family":"Gonzalez-Reiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-3842","authenticated-orcid":false,"given":"Adriana","family":"van de Guchte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PARIS","family":"study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-3051","authenticated-orcid":false,"given":"Emilia Mia","family":"Sordillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Noah","family":"Sather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm","family":"van Bakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6416-5096","authenticated-orcid":false,"given":"Viviana","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7830","key":"10.1016\/j.ebiom.2021.103626_bib0001","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103626_bib0002","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103626_bib0003","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2021.103626_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","author":"Thomson","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103626_bib0005","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.5.210009","article-title":"Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020","volume":"26","author":"Larsen","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ebiom.2021.103626_bib0006","unstructured":"Public Health England (PHE). Investigation of novel SARS-CoV-2 variant of concern. Technical briefing 5. [Webpage]. Dec 01, 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959426\/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf. [Accessed Oct 09, 2021]."},{"issue":"7854","key":"10.1016\/j.ebiom.2021.103626_bib0007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"issue":"6544","key":"10.1016\/j.ebiom.2021.103626_bib0008","first-page":"815","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus","volume":"372","author":"Faria","year":"2021","journal-title":"Braz Sci"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103626_bib0009","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"19","key":"10.1016\/j.ebiom.2021.103626_bib0010","doi-asserted-by":"crossref","first-page":"712","DOI":"10.15585\/mmwr.mm7019e1","article-title":"Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ebiom.2021.103626_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03908-2","article-title":"Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York","author":"Annavajhala","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2021.103626_bib0012","article-title":"SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2021.103626_bib0013","article-title":"The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America","author":"Romero","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ebiom.2021.103626_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab082","article-title":"Second wave of COVID-19: emergency situation in India","author":"Kumar","year":"2021","journal-title":"J Travel Med"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103626_bib0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41564-021-00933-9","article-title":"Emergence and spread of a SARS-CoV-2 lineage a variant (A.23.1) with altered spike protein in Uganda","volume":"6","author":"Bugembe","year":"2021","journal-title":"Nat Microbiol"},{"issue":"15","key":"10.1016\/j.ebiom.2021.103626_bib0016","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","volume":"184","author":"Amanat","year":"2021","journal-title":"Cell"},{"issue":"32","key":"10.1016\/j.ebiom.2021.103626_bib0017","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103626_bib0018","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103626_bib0019","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr Protoc Microbiol"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103626_bib0020","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.2021.2294","article-title":"SARS-CoV-2 variants of concern in the United States-challenges and opportunities","volume":"325","author":"Walensky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2021.103626_bib0021","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1917","article-title":"Introductions and early spread of SARS-CoV-2 in the New York City area","author":"Gonzalez-Reiche","year":"2020","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ebiom.2021.103626_bib0022","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103626_bib0023","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ebiom.2021.103626_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veab064","article-title":"Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool","author":"O'Toole","year":"2021","journal-title":"Virus Evol"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103626_bib0025","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103626_bib0026","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103626_bib0027","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149154","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J Clin Invest"},{"issue":"7847","key":"10.1016\/j.ebiom.2021.103626_bib0028","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"issue":"10283","key":"10.1016\/j.ebiom.2021.103626_bib0029","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(21)00782-0","article-title":"Correlates of protection from SARS-CoV-2 infection","volume":"397","author":"Krammer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2021.103626_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2021.103626_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"SARS-CoV-2 spike E484K mutation reduces antibody neutralisation","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103626_bib0032","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103626_bib0033","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","author":"Edara","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103626_bib0035","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103626_bib0036","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.ebiom.2021.103626_bib0037","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ebiom.2021.103626_bib0038","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103626_bib0039","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2104974","article-title":"Vaccination NSGfC-. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103626_bib0040","article-title":"SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum","author":"Tada","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ebiom.2021.103626_bib0041","article-title":"SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance","author":"Kimura","year":"2021","journal-title":"bioRxiv"},{"issue":"10293","key":"10.1016\/j.ebiom.2021.103626_bib0042","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103626_bib0043","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103626_bib0044","article-title":"Effectiveness of COVID-19 vaccines against variants of concern, Canada","author":"Nasreen","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ebiom.2021.103626_bib0045","article-title":"Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","author":"Pouwels","year":"2021","journal-title":"medRxiv"},{"issue":"34","key":"10.1016\/j.ebiom.2021.103626_bib0046","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.ebiom.2021.103626_bib0047","article-title":"Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant","author":"Li","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ebiom.2021.103626_bib0048","first-page":"1","article-title":"The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus","volume":"2021","author":"Liu","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.ebiom.2021.103626_bib0049","article-title":"SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity","author":"Saito","year":"2021","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103626_bib0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103626_bib0051","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola Virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103626_bib0052","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103626_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01696-18","article-title":"Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice","volume":"93","author":"Asthagiri Arunkumar","year":"2019","journal-title":"J Virol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:12:14Z","timestamp":1762456334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421004199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"alternative-id":["S2352396421004199"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103626","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.21.21260961","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103626"}}